| 000 | 01874 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250517044117.0 | ||
| 264 | 0 | _c20160919 | |
| 008 | 201609s 0 0 eng d | ||
| 022 | _a1860-7187 | ||
| 024 | 7 |
_a10.1002/cmdc.201500218 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aNettekoven, Matthias | |
| 245 | 0 | 0 |
_aNovel Triazolopyrimidine-Derived Cannabinoid Receptor 2 Agonists as Potential Treatment for Inflammatory Kidney Diseases. _h[electronic resource] |
| 260 |
_bChemMedChem _cJan 2016 |
||
| 300 |
_a179-89 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAnti-Inflammatory Agents, Non-Steroidal _xchemical synthesis |
| 650 | 0 | 4 |
_aCannabinoid Receptor Agonists _xchemical synthesis |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInflammation _xdrug therapy |
| 650 | 0 | 4 |
_aKidney Diseases _xdrug therapy |
| 650 | 0 | 4 | _aModels, Molecular |
| 650 | 0 | 4 | _aMolecular Structure |
| 650 | 0 | 4 |
_aPyrimidines _xchemical synthesis |
| 650 | 0 | 4 |
_aReceptor, Cannabinoid, CB2 _xagonists |
| 650 | 0 | 4 | _aStructure-Activity Relationship |
| 650 | 0 | 4 |
_aTriazoles _xchemical synthesis |
| 700 | 1 | _aAdam, Jean-Michel | |
| 700 | 1 | _aBendels, Stefanie | |
| 700 | 1 | _aBissantz, Catarina | |
| 700 | 1 | _aFingerle, Jürgen | |
| 700 | 1 | _aGrether, Uwe | |
| 700 | 1 | _aGrüner, Sabine | |
| 700 | 1 | _aGuba, Wolfgang | |
| 700 | 1 | _aKimbara, Atsushi | |
| 700 | 1 | _aOttaviani, Giorgio | |
| 700 | 1 | _aPüllmann, Bernd | |
| 700 | 1 | _aRogers-Evans, Mark | |
| 700 | 1 | _aRöver, Stephan | |
| 700 | 1 | _aRothenhäusler, Benno | |
| 700 | 1 | _aSchmitt, Sebastien | |
| 700 | 1 | _aSchuler, Franz | |
| 700 | 1 | _aSchulz-Gasch, Tanja | |
| 700 | 1 | _aUllmer, Christoph | |
| 773 | 0 |
_tChemMedChem _gvol. 11 _gno. 2 _gp. 179-89 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/cmdc.201500218 _zAvailable from publisher's website |
| 999 |
_c25126312 _d25126312 |
||